Research
And Grants
Note: When clicking the "Submit Grant Application" button below you will be redirected to SnapGrant.com to complete the application process.
Submit Grant ApplicationThe Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.
The Cure Starts Now has funded $23,988,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 154 grants at over 100 hospitals in 29 countries.
The Hospital For Sick Children (SickKids) – $100,000
$100,000.00
November 2022
Synthetic lethality screening with methionine restriction for treatment of DIPG
University of Texas MD Anderson Cancer Center – $100,000
$100,000.00
November 2022
Viroimmunotherapy for pediatric brain tumors
Hunter Medical Research Institute – $200,000
$200,000.00
November 2022
DMG COMBATT 2.0: Diffuse Midline Glioma COMbined Anti-Tumor Targeting 2.0
The Institute of Cancer Research – $501,183
$501,183.00
November 2022
Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG)
Cincinnati Children's Hospital – $50,000
$50,000.00
May 2022
Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma
SIOPe DIPG/DMG Registry – $779,018
$779,018.00
March 2022
Renewal of the European DIPG/DMG Registry
Funding of PBTCF 2022 - $25,000
$25,000.00
January 2022
Massachusetts General Hospital – $50,000
$50,000.00
November 2021
Targeted Protein Degradation for DIPG Therapy
CONNECT2007 - $345,794
$345,794.00
September 2021
Phase I/II Study of Lutathera in Pediatric and Young Adult Patients with Recurrent and/or Progressive High-Grade Central Nervous System (CNS) Tumors and Meningiomas which Express Somatostatin Type 2A Receptors and Demonstrate Uptake on DOTATATE
CONNECT2109A - $705,764
$705,764.00
September 2021
CONNECT2109A: A molecularly-guided phase II study of ribociclib and everolimus in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG)
CONNECT Consortium - $278,619
$278,619.00
September 2021
Immuno-Modulation to Treat Poor-Prognosis Pediatric Brain Tumors
Institute of Cancer Research – $113,747
$113,747.00
September 2021
Co-Culture Disruptor Screens to Target Cell-Cell Interactions in DMG
Institute of Cancer Research – $498,716
$498,716.00
September 2021
Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) - An International Connect Consortium Preclinical / Clinical
Sydney Children’s Hospital – $195,327
$195,327.00
September 2021
Phase I/II Study of Oral DFMO and AMXT1501 for DIPG/DMG
Children’s Hospital of Colorado – $200,000
$200,000.00
September 2021
Multimodality, Combination Treatment Strategy for DIPG/DMG